High-dose flu vaccine tied to lower Alzheimer’s risk in older adults

 With your risk of dementia post stroke a competent? doctor and hospital would immediately get this into a protocol! 

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

OH NO! your doctor KNOWS NOTHING AND DOES NOTHING! 

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this! Is s/he willing to prevent this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

High-dose flu vaccine tied to lower Alzheimer’s risk in older adults

 

High-dose inactivated influenza vaccine (H-IIV) was associated with a significantly lower risk of incident Alzheimer's disease (AD) compared with standard-dose inactivated influenza vaccine (S-IIV) in adults aged 65 years and older, with the protective effect more pronounced and sustained in women than in men, according to a retrospective cohort study published in Neurology.

Avram Samuel Bukhbinder, The McGovern Medical School at UTHealth, Houston, Texas, and colleagues found that H-IIV was associated with significantly lower AD risk during months 1-25 post-vaccination, with a minimum number needed to treat (NNT) of 185.2 at month 25. Following sex stratification, the risk reduction persisted for longer among women (months 1-13; minimum NNT, 416.7) than men, in whom significance was observed only during months 17-24 in the intention-to-treat analysis (minimum NNT, 232.6).

For the study, researchers analysed claims data spanning 2014-2019 from a large US healthcare claims database. Eligible participants were aged 65 years or older with at least 2 years of continuous medical and pharmaceutical coverage and no prior diagnostic or pharmacotherapeutic indicators of cognitive impairment. Participants were followed for up to 3 years post-vaccination, with incident AD defined using International Classification of Diseases codes and dispensing records for AD medications, including anticholinesterase inhibitors and memantine.

The H-IIV group comprised 120,775 unique participants (185,183 person-trials; mean age 74.4 years; 57.3% female), whilst the S-IIV group included 44,022 participants (53,918 person-trials; mean age 73.0 years; 56.4% female). 

The authors noted that previous large cohort analyses comparing vaccinated and unvaccinated adults have suggested that routine immunisations, including inactivated influenza vaccines, may reduce AD risk, but whether this risk differed according to vaccine dose had not previously been examined. 

"This study demonstrated a decreased risk of incident AD among adults [aged] ≥65 years who received a high-dose influenza vaccine versus a standard-dose influenza vaccine, with a longer and more robust effect among women than men" the authors wrote, whilst acknowledging that significant study limitations included a follow-up duration of 3 years or fewer and the absence of sociodemographic, lifestyle, biomarker, and mortality data.

The authors called for longitudinal and prospective studies with diverse populations, comprehensive cognitive assessments, and follow-up periods comparable to the decades-long preclinical phase of AD. They also highlighted the need to clarify the mechanisms underlying the apparent dose-dependent effect, including "the extent to which this effect is mediated by greater protection against influenza infection or by nonmicrobial pathways (eg, trained immunity, inflammaging)." Future research should also examine whether influenza vaccination influences clinical progression from mild cognitive impairment to AD.

Source: Neurology